UNCY (Unicycive Therapeutics) EBITDA Margin %: 0.00% (As of Mar. 2026)


UNCY Unicycive Therapeutics Inc UNCY
30 GF Score
Price $5.73
! 2 Warning Signs
View Full Analysis

What is Unicycive Therapeutics EBITDA Margin %?

Unicycive Therapeutics UNCY +8.52% 30 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates UNCY with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 939 Biotechnology companies, Unicycive Therapeutics ranks worse than 106496.17% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Unicycive Therapeutics's EBITDA for the three months ended in Mar. 2026 was $-12.61 Mil. Unicycive Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Unicycive Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Unicycive Therapeutics  (NAS:UNCY) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Unicycive Therapeutics EBITDA Margin % Related Terms

Unicycive Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Unicycive Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Unicycive Therapeutics EBITDA Margin % Chart

Unicycive Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial 0.00 -1,881.28 -4,470.81 0.00 0.00

Unicycive Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

UNCY vs MDWD, ARCT, NGEN: EBITDA Margin % Comparison

For the Biotechnology subindustry, Unicycive Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Unicycive Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Unicycive Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Unicycive Therapeutics's EBITDA Margin % falls into.


UNCY
30GF Score
Unicycive Therapeutics Inc UNCY
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Unicycive Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Unicycive Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-25.912/0
= %

Unicycive Therapeutics's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-12.612/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Unicycive Therapeutics (UNCY) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Unicycive Therapeutics and its competitors. According to the industry distribution chart, Unicycive Therapeutics ranks #999999 out of 939 companies in the Biotechnology industry.
Is Unicycive Therapeutics' EBITDA Margin % too high?
Unicycive Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Unicycive Therapeutics ranks #999999 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Unicycive Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Unicycive Therapeutics' EBITDA Margin % compare to MDWD and ARCT?
According to the Biotechnology industry distribution chart, Unicycive Therapeutics ranks #999999 out of 939 companies for EBITDA Margin %. This places Unicycive Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Unicycive Therapeutics and its competitors. Unicycive Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unicycive Therapeutics stock overvalued right now?
Unicycive Therapeutics (UNCY) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Unicycive Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Unicycive Therapeutics (UNCY), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Unicycive Therapeutics Business Description

Address 1975 W. El Camino Real, Suite 204, Mountain View, CA, USA, 94040
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
30GF Score

Get the complete analysis for UNCY

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.73
Price